VM BioPharma doses first patient in Phase III trial of VM202 to treat DPN
US-based ViroMed’s biopharmaceutical company division VM BioPharma has dosed the first patient in its Phase III clinical trial of a patented DNA-based gene therapy, VM202, to treat painful diabetic peripheral neuropathy (DPN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Gene Therapy | Genetics | Neurology | Peripheral Neuropathy | Pharmaceuticals